Xilio Therapeutics (XLO) Assets (2020 - 2026)
Xilio Therapeutics (XLO) posted Assets of $163.5 million for Q1 2026, up 5.69% sequentially from $154.7 million in Q4 2025, and up 57.63% YoY from $103.7 million in Q1 2025.
Xilio Therapeutics (XLO) Assets (2020 - 2026) Analysis & Trends
Xilio Therapeutics has reported Assets for 7 years, with the latest figure at $163.5 million in Q1 2026.
- Quarterly Assets rose 57.63% year-over-year to $163.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $163.5 million (up 57.63% YoY) and the FY2025 annual result came in at $154.7 million, up 117.64% from the prior year.
- Assets climbed to $163.5 million in Q1 2026 per XLO's latest filing, from $154.7 million in the prior quarter.
- Over five years, Assets peaked at $196.4 million in Q1 2022 and troughed at $60.9 million in Q4 2023.
- A 5-year average of $118.9 million and a median of $111.5 million in 2023 frame the typical range for Assets.
- The sharpest annual moves came in 2023 and 2025: Assets sank 56.22% in 2023, then jumped 117.64% in 2025.
- Over 5 years, Assets stood at $139.2 million in 2022, then tumbled by 56.22% to $60.9 million in 2023, then gained by 16.66% to $71.1 million in 2024, then surged by 117.64% to $154.7 million in 2025, then advanced by 5.69% to $163.5 million in 2026.
- According to Business Quant data, Assets over the past three periods registered $163.5 million, $154.7 million, and $133.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.56 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.10 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.60 Bn |
| 10 | Xilio Therapeutics | 177.75 Mn | 41.71 Mn | - | 154.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 154.25 Mn |
| Mar 31, 2026 | 163.49 Mn |
| Dec 31, 2025 | 154.69 Mn |
| Sep 30, 2025 | 133.69 Mn |
| Jun 30, 2025 | 133.81 Mn |
| Mar 31, 2025 | 103.72 Mn |
| Dec 31, 2024 | 71.08 Mn |
| Sep 30, 2024 | 74.66 Mn |
| Jun 30, 2024 | 89.87 Mn |
| Mar 31, 2024 | 82.61 Mn |
| Dec 31, 2023 | 60.93 Mn |
| Sep 30, 2023 | 77.84 Mn |
| Jun 30, 2023 | 92.36 Mn |
| Mar 31, 2023 | 111.51 Mn |
| Dec 31, 2022 | 139.17 Mn |
| Sep 30, 2022 | 157.41 Mn |
| Jun 30, 2022 | 178.13 Mn |
| Mar 31, 2022 | 196.35 Mn |
| Dec 31, 2021 | 218.06 Mn |
| Sep 30, 2021 | 120.73 Mn |